Design of full-length agonist and antagonist antibodies for hard targets
Therapeutic antibodies have transformed modern medicine, yet conventional discovery relies on lengthy experimental workflows, offers limited control over how antibodies engage their targets, and struggles to deliver candidates across many important target classes. Despite recent advances in computational protein design, generating full-length antibodies with desired functional activity and…
We haven't written up this one. bioRxiv has the full story — the link below goes straight to it.
